Critical Care Therapeutics in Major Developed Markets
Albumin was used to treat the highest share of the critical care patient population across all eight markets in 2013, with 2.2 million patients out of a total 2.4 million. GBI Research forecasts that albumin demand will increase at a CAGR of 15–20% over the next few years, and the approval of additional indications, such as treatment for Alzheimer’s disease, could contribute towards this growth.